This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (3)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Neurology  • Neuro-ophthalmology  • Glaucoma  • Alert me on articles by topic

Hani Levkovitch-Verbin, MD; Maia Kalev-Landoy, MD; Zohar Habot-Wilner, MD; Shlomo Melamed, MD

Arch Ophthalmol. 2006;124:520-526.

Objective  To evaluate the effect of minocycline hydrochloride on the survival of retinal ganglion cells (RGCs) in glaucomatous rat eyes and rat eyes after optic nerve transection (ONT).

Methods  The effect of intraperitoneal injections of minocycline at dosages of 15 mg/kg per day, 22 mg/kg per day, and 45 mg/kg per day was evaluated and compared with saline in ONT (n = 174) and experimental glaucoma (n = 51).

Results  The mean ± SEM survival rate of RGCs 1 week after ONT was significantly higher with minocycline at dosages of 15 mg/kg per day (36% ± 3%; n = 9; P = .04), 22 mg/kg per day (44% ± 2%; n = 15; P = .001), and 45 mg/kg per day (39% ± 3%; n = 10; P = .008) compared with saline (29% ± 2%; n = 28). Minocycline at a dosage of 22 mg/kg per day was also significantly neuroprotective compared with saline 2 weeks after ONT (mean ± SEM survival rate, 5% ± 1% vs 3% ± 0.4%, respectively; n = 20 [10 rats in each group]; P = .03). In experimental glaucoma, the mean ± SEM percentage of RGCs after 4 weeks was 84% ± 4% in the minocycline group (n = 15) compared with 65% ± 4% in the saline group (n = 18) (P = .003). Apoptosis of RGCs was significantly delayed by minocycline 4 days and 1 week after ONT.

Conclusion  Minocycline significantly enhances the survival of RGCs after ONT and in experimental glaucoma by delaying the apoptosis pathway.

Clinical Relevance  The safety record of minocycline and its ability to penetrate the blood-brain barrier suggest that this drug is a promising neuroprotective drug for optic nerve injuries.

Author Affiliations: Sam Rothberg Ophthalmic Molecular Biology Laboratory, Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Reduced Retina Microglial Activation and Improved Optic Nerve Integrity with Minocycline Treatment in the DBA/2J Mouse Model of Glaucoma
Bosco et al.
IOVS 2008;49:1437-1446.
ABSTRACT | FULL TEXT  

Tumor Necrosis Factor-{alpha} Mediates Oligodendrocyte Death and Delayed Retinal Ganglion Cell Loss in a Mouse Model of Glaucoma
Nakazawa et al.
J. Neurosci. 2006;26:12633-12641.
ABSTRACT | FULL TEXT